CapecitabineRecent, repeatedEvidence- NCT07829757 · Astellas Pharma Inc · Phase 4 · live · background · “Capecitabine” · registered Sep 2026
- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Capecitabine” · registered Sep 2026
- NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Capecitabine” · registered Aug 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Capecitabine” · registered Feb 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · background · “Capecitabine” · registered Jan 2026
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 1117 studies | 1222 studies | background 47 · comparator 2 |
OxaliplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07829757 · Astellas Pharma Inc · Phase 4 · live · background · “Oxaliplatin” · registered Sep 2026
- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Oxaliplatin” · registered Sep 2026
- NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Oxaliplatin” · registered Aug 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Oxaliplatin” · registered Feb 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “Oxaliplatin” · registered Jan 2026
| Sanofi35% of its industry studies | 1116 studies | 1121 studies | background 47 · comparator 4 |
NivolumabRecent, repeatedEvidence- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Nivolumab” · registered Sep 2026
- NCT07700979 · Akeso · Phase 3 · live · comparator · “Nivolumab” · registered Jul 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Nivolumab” · registered Feb 2026
- NCT07392892 · Pfizer · Phase 3 · live · comparator · “Nivolumab” · registered Jan 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · background · “Nivolumab” · registered Jan 2026
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 1011 studies | 1213 studies | background 15 · comparator 3 |
pembrolizumabRecent, repeatedEvidence- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07332533 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Pembolizumab” · registered Dec 2025
- NCT07315750 · RemeGen Co., Ltd. · Phase 3 · live · comparator · “Pembrolizumab” · registered Dec 2025
- NCT06998771 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Pembolizumab” · registered May 2025
- NCT06764875 · AstraZeneca · Phase 3 · live · comparator · “Pembrolizumab” · registered Dec 2024
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 910 studies | 1012 studies | background 13 · comparator 5 |
TrastuzumabRecent, repeatedEvidence- NCT07332533 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Trastuzumab” · registered Dec 2025
- NCT07315750 · RemeGen Co., Ltd. · Phase 3 · live · background · “Trastuzumab” · registered Dec 2025
- NCT07040059 · Dr. Reddy's Laboratories Limited · Phase 2 · comparator · “Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)” · registered Jun 2025
- NCT06998771 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Trastuzumab” · registered May 2025
- NCT06764875 · AstraZeneca · Phase 3 · live · comparator · “Trastuzumab” · registered Dec 2024
| Hoffmann-La Roche55% of its industry studiesUS: Hoffmann-La Roche (FDA 1998) + 6 othersEU: Hoffmann-La Roche (EMA 2000) + 8 others | 911 studies | 812 studies | background 15 · comparator 9 |
PaclitaxelRecent, repeatedEvidence- NCT07518147 · Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2026
- NCT06346392 · AstraZeneca · Phase 3 · live · background · “Ramucirumab+ paclitaxel” · registered Feb 2024
- NCT06123494 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan” · registered Nov 2023
- NCT06038578 · Toray Industries, Inc · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 77 studies | 911 studies | background 16 · comparator 8 |
FluorouracilRecent, repeatedEvidence- NCT07829757 · Astellas Pharma Inc · Phase 4 · live · background · “5-fluorouracil” · registered Sep 2026
- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Fluorouracil” · registered Sep 2026
- NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “5-Fluorouracil” · registered Aug 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “5Fluorouracil” · registered Feb 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “5-Fluorouracil” · registered Jan 2026
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 712 studies | 815 studies | background 36 · comparator 4 |
IrinotecanRecent, repeatedEvidence- NCT07518147 · Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Irinotecan hydrochloride” · registered Apr 2026
- NCT07364422 · Jeil Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Irinotecan (drug)” · registered Jan 2026
- NCT06346392 · AstraZeneca · Phase 3 · live · background · “Irinotecan” · registered Feb 2024
- NCT06219941 · AstraZeneca · Phase 2 · live · background · “Irinotecan” · registered Nov 2023
- NCT06123494 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan” · registered Nov 2023
| Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016) | 67 studies | 79 studies | comparator 6 · background 9 |
DocetaxelRecent, repeatedEvidence- NCT07518147 · Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Docetaxel” · registered Apr 2026
- NCT06947291 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Docetaxel for Injection (Albumin-bound)” · registered Apr 2025
- NCT06346392 · AstraZeneca · Phase 3 · live · background · “Docetaxel” · registered Feb 2024
- NCT06296706 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Taxotere (docetaxel)” · registered Feb 2024
- NCT06123494 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan” · registered Nov 2023
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 57 studies | 911 studies | comparator 5 · background 15 |
LeucovorinRecent, repeatedEvidence- NCT07829757 · Astellas Pharma Inc · Phase 4 · live · background · “Folinic Acid” · registered Sep 2026
- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Leucovorin Calcium” · registered Sep 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Leucovorin” · registered Feb 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “Leucovorin” · registered Jan 2026
- NCT07069712 · AstraZeneca · Phase 2 · live · background · “Calcium folinate” · registered Jun 2025
| Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed | 58 studies | 59 studies | background 21 · comparator 1 |
CAPOX RegimenRecent, repeatedEvidence- NCT07700979 · Akeso · Phase 3 · live · background · “CAPOX regimen” · registered Jul 2026
- NCT07315750 · RemeGen Co., Ltd. · Phase 3 · live · comparator · “CAPOX (oxaliplatin/capecitabine)” · registered Dec 2025
- NCT07221149 · Bristol-Myers Squibb · Phase 3 · live · background · “Capox” · registered Oct 2025
- NCT07040059 · Dr. Reddy's Laboratories Limited · Phase 2 · comparator · “Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)” · registered Jun 2025
- NCT05322577 · Amgen · Phase 2 · background · “CAPOX” · registered Apr 2022
| — | 55 studies | 33 studies | background 3 · comparator 2 |
RamucirumabRecent, repeatedEvidence- NCT06346392 · AstraZeneca · Phase 3 · live · background · “Ramucirumab+ paclitaxel” · registered Feb 2024
- NCT06123494 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan” · registered Nov 2023
- NCT06038578 · Toray Industries, Inc · Phase 2 · live · background · “Ramucirumab” · registered Aug 2023
- NCT05311176 · Imugene Limited · Phase 2 · background · “Ramucirumab plus Paclitaxel” · registered Mar 2022
- NCT04704934 · Daiichi Sankyo · Phase 3 · live · comparator · “Ramucirumab” · registered Jan 2021
| Eli Lilly and Company91% of its industry studiesUS: Eli Lilly and Company (FDA 2014)EU: Eli Lilly and Company (EMA 2014) | 44 studies | 44 studies | background 3 · comparator 3 |
CisplatinRecent, repeatedEvidence- NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Cisplatin” · registered Aug 2026
- NCT07332533 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Cisplatin” · registered Dec 2025
- NCT06764875 · AstraZeneca · Phase 3 · live · comparator · “Cisplatin” · registered Dec 2024
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Jul 2022
- NCT05152147 · Jazz Pharmaceuticals · Phase 3 · live · background · “Cisplatin” · registered Nov 2021
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 34 studies | 57 studies | background 29 · comparator 4 |
BevacizumabRecent, repeatedEvidence- NCT06730750 · Bristol-Myers Squibb · Phase 2 · live · background · “Bevacizumab” · registered Dec 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Jul 2022
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Bevacizumab” · registered Aug 2021
- NCT03929666 · Jazz Pharmaceuticals · Phase 2 · background · “Bevacizumab” · registered Feb 2019
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 33 studies | 34 studies | background 6 |
GemcitabineRecent, repeatedEvidence- NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Gemcitabine” · registered Aug 2026
- NCT06219941 · AstraZeneca · Phase 2 · live · background · “Gemcitabine” · registered Nov 2023
- NCT05173142 · HUTCHMED · Phase 2 · background · “gemcitabine and cisplatin” · registered Oct 2021
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Gemcitabine” · registered Aug 2021
- NCT04683939 · BioNTech SE · Phase 2 · background · “Gemcitabine” · registered Dec 2020
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 22 studies | 44 studies | background 8 |
Antineoplastic AgentsRecent, repeatedEvidence- NCT07392892 · Pfizer · Phase 3 · live · background · “Chemotherapy” · registered Jan 2026
- NCT06731478 · Daiichi Sankyo · Phase 3 · live · background · “Chemotherapy” · registered Dec 2024
- NCT05111626 · Amgen · Phase 3 · background · “Chemotherapy” · registered Oct 2021
- NCT04868877 · Genmab · Phase 2 · background · “Chemotherapy” · registered Apr 2021
- NCT02873520 · Ningbo Cancer Hospital · Phase 2 · background · “Chemotherapy” · registered Aug 2016
| — | 22 studies | 22 studies | background 6 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Jul 2022
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Carboplatin” · registered Aug 2021
- NCT04644068 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Oct 2020
| Eli Lilly and Company16% of its industry studies | 22 studies | 23 studies | background 4 |
LevoleucovorinRecent, repeatedEvidence- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Levoleucovorin” · registered Sep 2026
- NCT06219941 · AstraZeneca · Phase 2 · live · background · “l-leucovorin” · registered Nov 2023
- NCT01590719 · Hoffmann-La Roche · Phase 2 · background · “Levofolinic acid” · registered May 2012
| Aurobindo Pharma100% of its industry studies | 22 studies | 22 studies | background 3 |
TegafurRecent, repeatedEvidence- NCT06256328 · Ono Pharmaceutical Co. Ltd · Phase 2 · live · background · “S-1” · registered Jan 2024
- NCT05322577 · Amgen · Phase 2 · background · “SOX” · registered Apr 2022
- NCT05144854 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “S-1” · registered Oct 2021
- NCT03662659 · Bristol-Myers Squibb · Phase 2 · background · “SOX” · registered Sep 2018
- NCT03615326 · Merck & Co., Inc · Phase 3 · background · “S-1” · registered Jul 2018
| Otsuka Holdings Co., Ltd.76% of its industry studies | 22 studies | 12 studies | background 8 |
gimeracilRecent, repeatedEvidence- NCT06256328 · Ono Pharmaceutical Co. Ltd · Phase 2 · live · background · “S-1” · registered Jan 2024
- NCT05322577 · Amgen · Phase 2 · background · “SOX” · registered Apr 2022
- NCT05144854 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “S-1” · registered Oct 2021
- NCT03662659 · Bristol-Myers Squibb · Phase 2 · background · “SOX” · registered Sep 2018
- NCT03615326 · Merck & Co., Inc · Phase 3 · background · “S-1” · registered Jul 2018
| Otsuka Holdings Co., Ltd.76% of its industry studies | 22 studies | 12 studies | background 9 |
Oxonic AcidRecent, repeatedEvidence- NCT06256328 · Ono Pharmaceutical Co. Ltd · Phase 2 · live · background · “S-1” · registered Jan 2024
- NCT05322577 · Amgen · Phase 2 · background · “SOX” · registered Apr 2022
- NCT05144854 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “S-1” · registered Oct 2021
- NCT03662659 · Bristol-Myers Squibb · Phase 2 · background · “SOX” · registered Sep 2018
- NCT03615326 · Merck & Co., Inc · Phase 3 · background · “S-1” · registered Jul 2018
| Otsuka Holdings Co., Ltd.76% of its industry studies | 22 studies | 12 studies | background 8 |
aldesleukinRecent, repeatedEvidence- NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Aldesleukin” · registered Feb 2022
- NCT05207722 · Celularity Incorporated · Phase 2 · background · “Recombinant Human Interleukin-2” · registered Jan 2022
- NCT04426669 · intima bioscience inc · Phase 2 · background · “Aldesleukin” · registered Jun 2020
| Chiron Corporation45% of its industry studiesUS: Chiron Corporation (FDA 1992) | 22 studies | 11 study | background 3 |
avelumabRecent, repeatedEvidence- NCT05419362 · Genome & Company · Phase 2 · background · “Avelumab” · registered Jun 2022
- NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Avelumab” · registered Feb 2022
- NCT02625623 · Merck KGaA, Darmstadt, Germany · Phase 3 · comparator · “Avelumab” · registered Dec 2015
| Pfizer44% of its industry studiesUS: Merck KGaA, Darmstadt, Germany (FDA 2017)EU: Merck KGaA, Darmstadt, Germany (EMA 2017) | 22 studies | 11 study | background 2 · comparator 1 |
atezolizumabRecent, repeatedEvidence- NCT06090318 · Rain Oncology Inc · Phase 2 · background · “Atezolizumab” · registered Nov 2022
- NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Atezolizumab” · registered Jan 2022
- NCT03829501 · Sanofi · Phase 2 · background · “Atezolizumab” · registered Jan 2019
| Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017) | 22 studies | 00 studies | background 3 |
CyclophosphamideRecent, repeatedEvidence- NCT05678205 · Artiva Biotherapeutics, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Dec 2022
- NCT05207722 · Celularity Incorporated · Phase 2 · background · “Cyclophosphamide” · registered Jan 2022
- NCT04426669 · intima bioscience inc · Phase 2 · background · “Cyclophosphamide” · registered Jun 2020
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 22 studies | 00 studies | background 3 |
fludarabineRecent, repeatedPhase 4 trial recordedEvidence- NCT05678205 · Artiva Biotherapeutics, Inc. · Phase 2 · background · “Fludarabine” · registered Dec 2022
- NCT05207722 · Celularity Incorporated · Phase 2 · background · “Fludarabine” · registered Jan 2022
- NCT04426669 · intima bioscience inc · Phase 2 · background · “Fludarabine” · registered Jun 2020
| Beijing Biotech18% of its industry studies | 22 studies | 00 studies | background 3 |